²¡ÀíѧÂÛÎÄ

Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ҽѧÂÛÎÄ > »ù´¡Ò½Ñ§ÂÛÎÄ > ²¡ÀíѧÂÛÎÄ >

Ö¬·¾Òò×ÓCTRP3ÓëÐÄѪ¹Ü¼²²¡¼°´úлÐÔ¼²²¡µÄ¹Øϵ

À´Ô´£ºÉúÀí¿Æѧ½øÕ¹ ×÷ÕߣººúÏþ;³£Ð¡Ù»;ËÎÑÓ±ò
·¢²¼ÓÚ£º2020-09-12 ¹²8940×Ö

¡¡¡¡Õª    Òª£º¡¡½üÄêÀ´Ðí¶àÑо¿±íÃ÷Ö¬·¾×éÖ¯×÷ΪÄÚ·ÖÃÚÆ÷¹ÙÔÚÈËÌå´úлÖÐÆð×Ų»¿É»òȱµÄ×÷Óá£Ñо¿·¢ÏÖ£¬Ö¬·¾×éÖ¯¿É·ÖÃÚ¶àÖÖÖ¬·¾Òò×Ó£¬ÕâЩ֬·¾Òò×Ó½«Ö¬·¾×éÖ¯¡¢´úл¼°¶àÖÖ¼²²¡ÁªÏµÔÚÒ»Æð¡£C1qÖ×Áö»µËÀÒò×Ó(TNF)Ïà¹Øµ°°×3(CTRP3)ÊÇÒ»ÖÖнü·¢ÏÖµÄÖ¬·¾Òò×Ó£¬ÊôÓÚC1q/TNF³¬¼Ò×壬ÓëÖ¬ÁªËØÓи߶ÈͬԴÐÔ¡£CTRP3ÒÔÄÚ·ÖÃڵķ½Ê½¶ÔÐÄѪ¹Ü¡¢´úл¡¢Ñ×Ö¢µÈÏà¹Ø¼²²¡·¢»Ó¶àÖÖ×÷Ó᣹ØÓÚCTRP3µÄÑо¿Ç÷ÓÚÉîÈëºÍ¶àÑù»¯£¬Òò´Ë±¾ÎĽ«Öصã²ûÊöCTRP3ÔÚÐÄѪ¹Ü¼°´úлÏà¹Ø¼²²¡·½Ãæ×îеÄÑо¿½øÕ¹£¬ÎªCTRP3µÄ½øÒ»²½Ñо¿ÌṩеÄÏßË÷¡£

¡¡¡¡¹Ø¼ü´Ê£º¡¡CTRP3; ÐÄѪ¹Ü¼²²¡; ´úлÐÔ¼²²¡;

¡¡¡¡Ëæ׿²²¡Æ׵ı仯£¬ÂýÐÔ²¡ÒÑÒýÆðÈËÃǵĹØ×¢¡£ÂýÐÔ¼²²¡£¬ÆäÌصãÊǽøÕ¹»ºÂý£¬²¡³Ì³¤£¬ËÀÍöÂʸߣ¬Õ¼È«ÊÀ½çËÀÍöÔ­ÒòµÄ60%ÒÔÉÏ[1]¡£ÐÄÄÔѪ¹Ü²¡¡¢ÌÇÄò²¡Êdz£¼ûµÄÂýÐÔ²¡£¬ÑÏÖØÓ°ÏìÈËÃǵÄÉíÌ彡¿µ¡£½üÄêÀ´·¢ÏÖÖ¬·¾×éÖ¯²»½ö½öÊÇÒ»¸öÖ¬Àà´úлÆ÷¹Ù£¬Æä·ÖÃڵĶàÖÖÖ¬·¾Òò×Ó¶ÔÈËÌå´úлÓÐ×ŶàÖÖ²»¿ÉºöÊÓµÄÓ°Ïì¡£CTRP3ÊÇÒ»ÖÖнü·¢ÏÖµÄCTRP¼Ò×åµÄÖ¬·¾Òò×Ó£¬ÓëÖ¬ÁªËØͬԴ[2]¡£µ½Ä¿Ç°ÎªÖ¹£¬ÒÑÓдóÁ¿¹ØÓÚCTRP3µÄÑо¿£¬Æ俹Ñס¢¿¹Ñõ»¯¡¢¿¹µòÍöµÈÌØÐÔʹÆäÔÚÐÄѪ¹Ü¼°´úлÐÔ¼²²¡·½ÃæÓкܴóµÄ±£»¤Ç±Á¦£¬ËùÒÔ±¾ÎÄ×ÛÊöÁËCTRP3ÔÚÕâЩ¼²²¡Ñо¿·½Ãæ×îеĽøÕ¹£¬ÒÔ±ãΪ½øÒ»²½¸üºÃµÄÑо¿CTRP3ÌṩÏßË÷¡£

¡¡¡¡Ò»¡¢CTRP3µÄ½á¹¹ºÍÊÜÌå

¡¡¡¡CTRP3Ò²±»ÃüÃûΪcors26¡¢cartducin¡¢cartoninc£¬¾ßÓÐһϵÁеÄN¶Ë½ºÔ­Öظ´ÐòÁÐ(Gly-x-y)ºÍ¸ß¶È±£ÊصÄC¶ËÇò×´½á¹¹Óò£¬ÊÇÖ¬·¾×éÖ¯·ÖÃÚµÄÒ»ÖÖÖ¬·¾Òò×Ó£¬ÓÉÁ½¸ö¼ô½ÓÌå×é³É£¬·Ö±ðΪCTRP3AºÍCTRP 3 B,CTRP3 A¿É·ÀÖ¹CTRP3 BÔÚѪÇåÖÐѸËÙ½µ½â[2]¡£

¡¡¡¡LiµÈÓ¦ÓÃеÄÅäÌåÊÜÌ岶»ñ·½·¨¼ø¶¨ÁËÈÜøÌåÏà¹ØĤµ°°×1(LAMP-1)ºÍÈÜøÌåĤµ°°×2(LIMP¢ò)ΪCTRP3Ôڸΰ©Ï¸°û(H4IIE)µÄDZÔÚÊÜÌå[2]¡£LAMP-1ºÍ/»òLIMP¢òÊÇ·ñÊÇCTRP3ÔÚÆäËûÀàÐÍϸ°ûµÄÊÜÌå²¢½éµ¼Æä·¢»ÓÒ»¶¨µÄ×÷ÓÃÈÔÐè½øÒ»²½Ñо¿Ö¤Êµ¡£ÈôÄܽÒʾCTRP3·¢»Ó×÷ÓõÄÊÜÌ彫¶ÔÆäÉúÎ﹦ÄܵÄ̽Ë÷¼°×÷ΪÁÙ´²ÖÎÁưе㽫Óм«´óµÄ´Ù½ø×÷Óá£
 

Ö¬·¾Òò×ÓCTRP3ÓëÐÄѪ¹Ü¼²²¡¼°´úлÐÔ¼²²¡µÄ¹Øϵ
 

¡¡¡¡¶þ¡¢CTRP3µÄ±í´ï

¡¡¡¡(Ò»)CTRP3µÄ×éÖ¯±í´ï

¡¡¡¡CTRP¼Ò×å³ÉÔ±±í´ï¹ã·º£¬ÄÔ¡¢ÐÄÔà¡¢·Î¡¢Æ¢Ôà¡¢ÉöÔà¡¢ÐØÏÙ¡¢Ö¬·¾×éÖ¯¡¢Èí¹Ç¡¢³ÉÏËάϸ°û¡¢Èí¹Çϸ°û¡¢Ñª¹Üƽ»¬¼¡Ï¸°û¡¢µ¥ºËϸ°ûºÍÂѳ²µÈ¶¼ÓÐCTRP3±í´ï[2]¡£ÄÚÔà(¸½Øº)°×É«Ö¬·¾×éÖ¯±í´ïµÄCTRP3ˮƽ¸ßÓÚƤÏÂ(¸¹¹É¹µ)°×É«Ö¬·¾×éÖ¯»ò¼çëμä×ØÉ«Ö¬·¾×éÖ¯[3]¡£KwonµÈ[4]·¢ÏÖCTRP3ÔÚÈéÖ­ÖеÄŨ¶È²îÒì½Ï´ó£¬·¶Î§ÔÚ2¡«80 ng/m L£¬¶øÇÒ·ÊÅÖĸÇ×(BMI>30 kg/m[2])µÄÈéÖ­ÖÐCTRP3±í´ïˮƽÃ÷ÏÔÉý¸ß£¬Í¬Ê±ÒȵºËغÍÊݵ°°×Ò²ÉÏÉý¡£Ä¸ÈéÖÐCTRP3ˮƽÊÇ·ñÓëѪÇåÖеÄCTRP3ˮƽÏà¹ØÓдý½øÒ»²½Ì½ÌÖ¡£Ñо¿ÏÔʾĸÈéιÑø¶Ô·ÊÅֺʹúлÎÉÂÒÓб£»¤×÷Ó㬷ÊÅÖĸÇ×ĸÈéÖеÄCTRP3ÊÇ·ñÓÐÀûÓÚ¶ùͯµÄ½¡¿µ¼°Æä¿ÉÄܵĻúÖÆÓдý½øÒ»²½²ûÃ÷¡£ChenµÈÈ˵ÄÑо¿±íÃ÷CTRP3²»½ö´æÔÚÓÚÆê´øѪÖУ¬¶øÇÒ¿ÉÄܲÎÓëÌ¥¶ùµÄÉú³¤·¢Óý£¬¹ýÆÚÈÑÉïÓ¤¶ùµÄѪÇåCTRP3ˮƽ¸ßÓÚÊʺÏÌ¥ÁäÓ¤¶ù[5]¡£È»¶øÆê´øѪÖÐCTRP3µÄÀ´Ô´ÈÔÓдýÑéÖ¤£¬¹ýÆÚÈÑÉïÓ¤¶ùѪÇåÖÐÔö¸ßµÄCTRP3ˮƽÊÇ·ñÖ»ÊDzÎÓëÁËÉú³¤·¢Óý£¬ÊÇ·ñÓÐÆäËû×÷ÓÃÉÐÐè½øÒ»²½Ñо¿¡£Ä¿Ç°Ã»ÓÐÖ±½ÓÖ¤¾Ý±íÃ÷Ó¤¶ùÖ®¼äµÄCTRP3ˮƽ´æÔÚÐÔ±ð²îÒ죬¶øÑо¿·¢ÏÖ³ÉÈ˵ÄCTRP3ѪÇåˮƽ´æÔÚÐÔ±ð²îÒ죬±íÃ÷ÐÔ¼¤ËØ¿ÉÄܲÎÓëµ÷½ÚÑ­»·CTRP3ˮƽ¡£±í1ÁгöÁËCTRP3ÓëÐÔ±ðºÍÆäËü±äÁ¿Ö®¼äµÄ¹Øϵ[6,7]¡£

¡¡¡¡±í1 CTRP3ÓëÐÔ±ð¼°ÆäËû±äÁ¿Ö®¼äµÄ¹Øϵ
±í1 CTRP3ÓëÐÔ±ð¼°ÆäËû±äÁ¿Ö®¼äµÄ¹Øϵ

¡¡¡¡“↑”±íÃ÷CTRP3±í´ïˮƽÔÚÊÜÊÔÕßÖÐÉÏÉý;“↑↑”±íÃ÷CTRP3ˮƽÏÔ×ÅÉÏÉý;“↓”±íÃ÷ÊÜÊÔÕßµÄCTRP3ˮƽϽµ;“-”±íÃ÷CTRP3ˮƽÎÞÏÔ×ű仯;“/”±íʾĿǰÎÞÑо¿±¨µ¼;T2D+CAD:2ÐÍÌÇÄò²¡²¢·¢¹Ú×´¶¯Âö¼²²¡;“↓↓”±íʾÊÜÊÔÕßCTRP3ˮƽÃ÷ÏÔϽµ

¡¡¡¡(¶þ)CTRP3ÓëÆäËûÖ¸±êµÄ¹Øϵ

¡¡¡¡CTRP3¿ÉÄÜÊÇÔ¤²â´úлÐÔ¼²²¡µÄÒ»¸öÉúÎï±êÖ¾ÎÑо¿·¢ÏÖCTRP3ÓëÐí¶àÐÄÔà´úлΣÏÕÒò×Ó³ÊÏÔןºÏà¹Ø¡£CTRP3ÓëÐÔ±ðÏà¹Ø¡£ÑªÇåCTRP3ˮƽÓëÖÖ×å(¶¨ÒåΪ°×È˺ͷǰ×ÈË)¡¢ÌåÖØÖ¸Êý¡¢¸ÊÓÍÈýõ¥¡¢ÑüΧ¡¢ÄÚÔàÖ¬·¾Ãæ»ý¡¢ÌåÖ¬¡¢ÌåÖ¬ÂÊ¡¢¹È±ûת°±Ã¸¡¢¿Õ¸¹ÑªÌÇ¡¢HbA1c¡¢¿Õ¸¹ÒȵºËØˮƽ¡¢HOMA-IRÖ¸Êý(ÆÀ¼ÛÒȵºËØÄÍÊܵÄÌåÄÚÎÈ̬ģÐÍ)¡¢CRP¡¢IL-6¡¢TG¡¢ÒȵºËØ¡¢µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼¡¢¸ÊÓÍÈýõ¥¡¢hs-CRPºÍ¾±¶¯ÂöÄÚĤÖвãºñ¶È(IMT)µÈ¸ºÏà¹Ø[6,8]¡£CTRP3Ũ¶ÈÓëHDL-C¡¢Ö¬ÁªËØ¡¢³öÉúÌåÖØzÆÀ·Ö¡¢Ì¥ÅÌÖØÁ¿µÈ³ÊÕýÏà¹Ø£¬¶àÒòËػعé·ÖÎöÏÔʾѪÇå¸ÊÓÍÈýõ¥ºÍhs-CRP¶ÔѪÇåCTRP3ˮƽÓÐÔ¤²â×÷ÓÃ[6,8]¡£ÕâЩÊý¾ÝÏÔʾÁËCTRP3ÓëÌÇ¡¢Ö¬´úл¼°Ñ×Ö¢µÄ¹Øϵ¼°ÆäÔÚÔ¤²âÏà¹Ø¼²²¡ÖеÄÓ¦ÓÃÇ°¾°¡£

¡¡¡¡Èý¡¢CTRP3ºÍÐÄѪ¹Ü¼²²¡

¡¡¡¡ÐÄË¥°éÉäѪ·ÖÊý½µµÍ(HFr EF)»¼ÕßµÄCTRP3ˮƽÓë×óÊÒÉäѪ·ÖÊýÕýÏà¹Ø£¬ÓëÄÔÄÆëĸºÏà¹Ø£¬²¢Óë¼²²¡µÄÑÏÖس̶ȳÉÕý±È£¬36¸öÔµÄËæ·Ãºó·¢ÏÖµÍÓÚ°Ù·ÖλÊý25µÄCTRP3ˮƽ¿ÉÔ¤²â×Ü·¢²¡ÂʺÍËÀÍöÂÊ[9]¡£Ñо¿±íÃ÷CTRP3¿Éͨ¹ýÒÖÖÆÑ×Ö¢¡¢¼õÇáÑõ»¯Ó¦¼¤¡¢ÔöÇ¿Ðļ¡ÊÕËõÁ¦¡¢´Ù½øÄÜÁ¿Éú³É¡¢¼õÇᲡÀíÐÔÖØËÜ¡¢´Ù½øѪ¹ÜÉú³ÉµÈ¶àÖÖ;¾¶¶ÔÐŦÄܲ»È«·¢»Ó±£»¤×÷ÓÃ(ͼ1)¡£CTRP3ÔÚÐÄѪ¹Ü·½ÃæµÄÑо¿×ܽá¼û±í2¡£

¡¡¡¡Í¼1 CTRP3µÄÐÄѪ¹ÜÉúÎïѧ¹¦ÄÜ×ܽá
ͼ1 CTRP3µÄÐÄѪ¹ÜÉúÎïѧ¹¦ÄÜ×ܽá

¡¡¡¡AMPK:AMP-activated protein kinase;Akt:protein kinase B;P38:Protein 38 MAPK;PGC-1α:peroxisome proliferator activated receptorγcoactivator-1α;c TnI:cardiac troponin I;tak1:transforming growth factorβ-activated kinase 1;PI3K:phosphatidylinositol 3-kinase;TLR4:Toll-like receptor;PPARγ:peroxisome proliferator-activated receptors

¡¡¡¡YiµÈ[10]֮ǰµÄʵÑéÖ¤Ã÷CTRP3ͨ¹ý¼¤»îAKT-HIF1α-VEGFÐźÅͨ·´Ù½øÐļ¡Ï¸°û-ÄÚƤϸ°ûÖ®¼äµÄÐźŽ»Á÷¶ø¼ä½Ó´Ù½ø¹£ËÀ±ßÔµÇøÐÂÉúѪ¹ÜÉú³É£¬¸ÄÉÆѪҺ¹àÁ÷£¬ÒÖÖƹ£ËÀÇøµÄÀ©´ó¡£ZhangµÈ[11]×î½ü·¢ÏÖCTRP3¿ÉÌá¸ßMSCs¶ÔСÊóÐļ¡¹£ËÀµÄÁÆЧ£¬ÔÚ¼ä³äÖÊ»ùÖÊϸ°û(MSCs)½øÐÐCTRP3¹ý±í´ïÌá¸ßÁËMSCsµÄ´æ»îºÍ±£Áô£¬²¢Ö¤Ã÷ÊÇͨ¹ý°üÀ¨ERK 1/2-MMP 9ºÍERK 1/2-Sod 2/MT1/2ÐźÅתµ¼»úÖÆʵÏÖÕâÖÖ×÷Óá£ÔٴδÓÄÚ·ÖÃÚµ÷½Ú½Ç¶ÈÖ¤Ã÷ÁËCTRP3¶ÔÐŦÄܵı£»¤×÷Óá£

¡¡¡¡Ðļ¡¹£ËÀºóµÄÐÄÊÒ²¡ÀíÐÔÖØËÜÑÏÖØÓ°ÏìÐĹ£ºóÐÄÔ๦ÄܵĻָ´¡£CTRP3ͨ¹ýÒÖÖÆÐļ¡³ÉÏËάϸ°ûµÄÔöÖ³¡¢Ç¨Òƺͼ¡³ÉÏËάϸ°ûµÄ·Ö»¯£¬¼õÇáÐļ¡¹£ËÀºóºÍת»¯Éú³¤Òò×Ó-β1(TGF-β1)ÓÕµ¼µÄÐļ¡ÏËά»¯£¬´Ó¶øÒÖÖÆÐļ¡¹£ËÀºóµÄÐÄÊÒ²¡ÀíÐÔÖØËÜ[10]¡£ZhangµÈ[12]ÔÚÊóÐļ¡·ÊºñÄ£ÐÍÖйý±í´ïCTRP3ºó¸ÄÉÆÁË×óÊÒÊÕËõ¹¦ÄÜ£¬¼õÇáÁËÐļ¡·ÊºñºÍÏËά»¯¡£²¢ÔÚÌåÍâʵÑéÖÐÖ¤Ã÷CTRP3¿ÉÒÖÖÆÉöÉÏÏÙËØÒýÆðµÄÔ­´úÐļ¡Ï¸°û·Ê´ó¡£CTRP3¿ÉÄÜÊÇͨ¹ýÒÖÖÆp38/CREBͨ·²¢¼õÇáÁËp38ÒýÆðµÄÄÚÖÊÍøÓ¦¼¤À´±£»¤Ñ¹Á¦³¬ÔØÒýÆðµÄÐÄÔಡÀíÐÔÖØËܺÍ×óÊÒ¹¦ÄÜʧµ÷¡£µ«ÊÇMaµÈ[13]µÄÑо¿±íÃ÷CTRP3ÔÚÐÄÔàͨ¹ýPKA¼¤»îÁËtak1-JNKÐźÅͨ·£¬ÒÔ×Ô·ÖÃڵķ½Ê½²ÎÓëÁËѹÁ¦³¬¸ººÉÒýÆðµÄÐļ¡·ÊºñµÄ·¢Õ¹¡£¹ØÓÚCTRP3ÔڷʺñÐÍÐļ¡²¡ºÍѹÁ¦³¬¸ººÉÐÔÐļ¡·ÊºñÈËȺÖеıí´ïˮƽÊÇ·ñÓвîÒìÉÐÎÞÏà¹ØÁÙ´²Ñо¿±¨µÀ¡£ÕâÖÖì¶ÜµÄ½á¹û¿ÉÄÜÊÇÓÉÓÚ²»Í¬µÄ¼²²¡Ä£ÐÍËùÖ£¬Ò²ÓпÉÄÜÊÇÖ¬·¾×éÖ¯ºÍÐļ¡Ï¸°ûÀ´Ô´µÄCTRP3·¢»Ó²»Í¬µÄ×÷Óá£ÓÐÑо¿±íÃ÷ÍʺÚËØ¿Éͨ¹ý´Ù½øÖ¬·¾×éÖ¯·ÖÃÚCTRP3¼õÉÙÐļ¡¹£ËÀºóµÄÓ¦¼¤·´Ó¦ºÍÏËά»¯£¬¶ø¶ÔÐļ¡Ï¸°û·ÖÃÚµÄCTRP3ûÓÐÓ°Ïì[19]¡£½øÒ»²½±íÃ÷ÁËÖ¬·¾×éÖ¯À´Ô´µÄCTRP3¶Ô²¡Àí״̬ÐÄÔàµÄ±£»¤×÷Ó㬺óÃæµÄÑо¿ÖпÉÄÜÒª¹Ø×¢Ðļ¡Ï¸°ûºÍÖ¬·¾×éÖ¯À´Ô´µÄCTRP3ÔÚÐļ¡µÄÑõ»¯Ó¦¼¤ÖÐ×÷ÓÃÊÇ·ñ²»Í¬£¬ÊÇ·ñÔÚÐÄѪ¹Ü¼²²¡Öзֱ𷢻Ӳ»Í¬µÄ×÷ÓÃ?

¡¡¡¡±í2 CTRP3ÔÚÐÄѪ¹ÜÖеÄÑо¿×ܽá
±í2 CTRP3ÔÚÐÄѪ¹ÜÖеÄÑо¿×ܽá

¡¡¡¡NRVCMs:neonatal rat ventricular cardiomyocytes;NRCMs:neonatal rat cardiomyocytes;MAECs:Mouse aortic endothelial cells;MSCs:Mesenchymal stromal cells;AS:atherosclerosis;DOX:doxorubicin;ERK:extracellular signal-regulated kinase;MMP:matrix metalloproteinase 9;CREB:c AMP response element binding protein;Sod2:superoxide dismutase 2;MT1/2:metallothionein 1/2

¡¡¡¡JiangµÈ[20]ÈÏΪCTRP3¿ÉÄÜͨ¹ýµ÷½ÚÑ×Ö¢¶øÓ°Ïìϸ°ûÍâ»ùÖʵŦÄÜ´Ó¶øÔÚ¼±ÐÔÖ÷¶¯Âö¼Ð²ãµÄ·¢Õ¹Öз¢»ÓÒ»¶¨×÷Óã¬Óë¸ßѪѹ×é¡¢Õý³£×éÏà±È£¬CTRP3±í´ïˮƽÔÚ¼±ÐÔÖ÷¶¯Âö¼Ð²ã(AAD)×éÖÐϽµ£¬ÇÒÓëTNF-αºÍIL-6µÈ¸ºÏà¹Ø¡£µ«ÊÇCTRP3ÔÚAADÖÐϽµµÄ¾ßÌå»úÖƼ°ÆäÔÚAADÖеÄ×÷ÓÃÉв»Çå³þ£¬ÔÚAADÄ£ÐÍÖнøÐÐCTRP3¹ý±í´ïÊÇ·ñ»áÓб£»¤×÷ÓÃ?ÇÒ±¾ÏîÑо¿·¢ÏÖÓëÕý³£ÈËȺÏà±È£¬¸ßѪѹ×éCTRP3ˮƽÎÞÃ÷ÏÔ²»Í¬£¬Óë֮ǰµÄÑо¿(DengµÈ£®2015)½á¹ûì¶Ü£¬¿ÉÄÜÓëÑù±¾Á¿½ÏС¡¢¸ßѪѹÑÏÖس̶ȡ¢´úл״¿öµÈÓйØϵ¡£CTRP3±í´ïˮƽÓë¸ßѪѹµÄ¹ØϵÈÔÐè´óÑù±¾Ñо¿Ö¤Êµ¡£

¡¡¡¡ËÄ¡¢CTRP3Óë´úлÐÔ¼²²¡

¡¡¡¡(Ò»)CTRP3Óë·ÊÅÖºÍÖ¬´úл

¡¡¡¡·ÊÅÖÒѳÉΪÊÀ½ç·¶Î§ÄڵĴóÁ÷ÐС£·ÊÅÖ¸öÌ廼·ÊÅÖ²¢·¢Ö¢µÄ·çÏսϸߣ¬Ö¬·¾Òò×ÓÔÚ·ÊÅֵķ¢Õ¹¹ý³ÌÖÐÆð×ÅÖØÒª×÷Ó᣷ÊÅÖ¸öÌåÖÐCTRP3ѪÇåˮƽÃ÷ÏÔµÍÓÚÊÝ×飬BMI¿ÉÄÜÊÇѪÇåCTRP3ˮƽµÄÔ¤²âÒò×Ó£¬µÍˮƽµÄCTRP3¿ÉÄÜÓë·ÊÅÖÏà¹ØµÄ´úлÎÉÂҵIJ¡ÀíÉúÀíѧÏà¹Ø(WolfµÈ£®2015)¡£3T3-L1Ö¬·¾Ï¸°û·Ö»¯¹ý³ÌÖÐCTRP3±í´ïˮƽ½µµÍ£¬½øÐÐCTRP3¹ý±í´ïºóÏÔ׎µµÍÁË3T3-L1Ö¬·¾Ï¸°ûÖеÄÖ¬Öʺ¬Á¿¼°Ö¬·¾ÐγÉÏà¹Ø±êÖ¾Î±íÃ÷CTRP3ÔÚÖ¬·¾Ï¸°û·Ö»¯¹ý³ÌÖпÉÄܸºÐÔµ÷½ÚÖ¬´úл[21]¡£WolfµÈ¶ÔСÊó½øÐÐCTRP3»ùÒòÇóýºó·¢ÏÖÆä¸ÎÔà¡¢Ö¬·¾¡¢ÑªÇåÖеÄTGFβ1±í´ïˮƽ½µµÍ£¬ÑªÇåIL-6ˮƽÔö¸ß¡£²¢ÇÒ·¢ÏÖιÑøµÍÖ¬»ò¸ßÖ¬Òûʳʱ¶ÔÆäÈ«ÉíÌÇ´úл¡¢ÒȵºËØÃô¸ÐÐÔ¡¢½ûʳÓÕµ¼µÄ¸ÎÌÇÒìÉú×÷ÓÃÓ°ÏìºÜС»òûÓÐÓ°Ï죬Ȼ¶ø¸ßÖ¬ÒûʳιÑøʱËüÃǵĸÎÔàÌå»ýÃ÷ÏÔ¼õС£¬¾¡¹ÜÆä¸ÊÓÍÈýõ¥º¬Á¿ÂÔÓÐÔö¼Ó¡£±íÃ÷CTRP3¿ÉÄÜÔÚµ÷½Ú·ÊÅÖÏà¹ØµÄ¸ÎÔà´óСºÍÑ­»·Ï¸°ûÒò×ÓˮƽÖз¢»Ó×ſ϶¨µÄ×÷ÓÃ[3]¡£CTRP3¿ÉÄÜÔÚÖ¬´úлÖз¢»ÓÒ»¶¨×÷Ó㬵«ÕâÖÖ×÷ÓÃÔÚÈ«ÉíÖ¬´úлµÄÉúÀíµ÷¿ØºÍ²¡Àí״̬ÏÂÊÇ·ñÓÐÒâÒåÐè½øÒ»²½Ñо¿¡£

¡¡¡¡(¶þ)CTRP3ÓëÌÇÄò²¡

¡¡¡¡CTRP3ˮƽÓë2ÐÍÌÇÄò²¡µÄ·¢Éú³Ê¸ºÏà¹Ø£¬ÊÇÓ°ÏìÒȵºËصֿ¹µÄ¶ÀÁ¢ÒòËØ[22]¡£ÑªÇåCTRP3ˮƽÔÚ2ÐÍÌÇÄò²¡(T2DM)»¼ÕßÖÐÃ÷ÏÔµÍÓÚ¶ÔÕÕ×飬ÔÚ½øÐпڷþÌÇÄÍÁ¿ÊÔÑéºóÃ÷ÏÔ½µµÍ(BanµÈ£®2014)¡£

¡¡¡¡LiµÈ(2014)ÍâÔ´ÐÔ¸øÓèCTRP3ºó½µµÍÁËÒȵºËصֿ¹3T3-L1Ö¬·¾Ï¸°ûµÄÌÇÉãÈ¡ºÍÏûºÄ¼°TNF-α¡¢IL-6µÈˮƽ£¬Ôö¼ÓÁËPI3KµÄµ°°×±í´ïˮƽ£¬²¢³Ê¼ÁÁ¿ÒÀÀµÐÔ£¬±íÃ÷CTRP3¿ÉÄÜͨ¹ý¼õÇáÑ×Ö¢¡¢ÔöÇ¿ÒȵºËØÐźŴ«µ¼µÈ;¾¶¸ÄÉÆÒȵºËصֿ¹3T3-L1Ö¬·¾Ï¸°ûµÄÒȵºËØÃô¸ÐÐÔ¡£ÔÚ´ÓÒȵºËصֿ¹µ½ÏÔÐÔÌÇÄò²¡·¢²¡½×¶ÎµÄT2DM´óÊóÄ£ÐÍÖУ¬CTRP3ÔÚÄÚÔàÖ¬·¾×éÖ¯Öеıí´ïÖð½¥½µµÍ£¬¶øExendin-4(GLP-1ÊÜÌ弤¶¯¼Á)ÔòÔö¼ÓÁËÆäÔÚÕâÀදÎïÖеıí´ï£¬²¢ÇÒÖ¤Ã÷ÊÇͨ¹ýPKAÐźÅͨ·Ôö¼Ó3T3-L1Ö¬·¾Ï¸°ûµÄCTRP3 mRNAºÍµ°°×±í´ï(LiµÈ£®2015)¡£ÒÔÉϽá¹ûÌáʾÁËCTRP3ÔÚ¸ÄÉÆÒȵºËصֿ¹ÖеÄ×÷Óá£Ã÷È·Exendin-4Ôö¼ÓCTRP3±í´ïˮƽµÄ»úÖÆÓÐÖúÓÚÀí½âCTRP3¶ÔÌÇ´úлµÄ¾ßÌå×÷Óá£

¡¡¡¡LiµÈ(2017)·¢ÏÖÈÑÉïÆÚÌÇÄò²¡»¼ÕߵĿո¹Ñª½¬CTRP3ˮƽÃ÷ÏÔµÍÓÚ¶ÔÕÕ×飬ÓëHDL-C¡¢HOMA-βÕýÏà¹Ø£¬ÓëÔÐÇ°ÌåÖØÖ¸Êý¡¢¿Õ¸¹ÑªÌÇ¡¢²ÍºóѪÌÇ¡¢HOMA-IR¡¢¸ÊÓÍÈýõ¥ºÍVLDL-C¸ºÏà¹Ø£¬²¢ÇÒ±íÃ÷¿Õ¸¹ÑªÌÇÊÇ¿Õ¸¹CTRP3ˮƽµÄ¶ÀÁ¢Ó°ÏìÒò×Ó¡£ÈÑÉïÆÚÌÇÄò²¡»¼Õß¿Õ¸¹ÑªÇåCTRP3ˮƽµÄ½µµÍ¿ÉÄÜÔÚÈÑÉïÆÚÌÇÄò²¡µÄ·¢²¡¹ý³ÌÖÐÆð×ÅÖØÒªµÄ´úл×÷Ó㬵«ÊÇÆäϽµµÄÔ­Òò¼°ÈçºÎÓ°ÏìÈÑÉïÆÚÌÇÄò²¡µÄ·¢Õ¹ÈÔÐè¼ÌÐøÑо¿¡£LiµÈÔÚ¶¯ÎïʵÑéÖз¢ÏÖÏà½ÏÓÚ·ÊÅÖ״̬£¬ÌåÖØÑ­»·¶ÔÖ¬·¾×éÖ¯¹¦ÄܵÄÓ°Ïì¸ü´ó£¬ÌåÖØÑ­»·Í¨¹ý½µµÍCTRP3¡¢PI3K¡¢Á×ËữPKB(Ser473)ºÍGLUT 4µÄ±í´ïˮƽ£¬Ôö¸ßIL-6ºÍTNF-α±í´ïˮƽ£¬´Ó¶øËðº¦ÌÇ´úлºÍÒȵºËØÃô¸ÐÐÔ[23]£¬ÌáʾÁËCTRP3ÔÚÌåÖØÑ­»·ÊóÖпÉÄÜͨ¹ý¿¹Ñ×µÈ×÷ÓöÔÌÇ´úлºÍÒȵºËØÄÍÊÜ·¢»Ó±£»¤×÷Ó᣺óÃæµÄʵÑéÖпɽøÐÐCTRP3µÄ¹ý±í´ï½øÒ»²½Ñо¿CTRP3¶ÔÌåÖØÑ­»·ÊóµÄÌÇ´úлºÍÒȵºËØÃô¸ÐÐÔµÄ×÷Óü°Æä·¢»Ó×÷ÓõÄÐźÅͨ·¡£

¡¡¡¡CTRP3¿ÉÄÜÓëÌÇÄò²¡µÄ²¢·¢Ö¢µÄ·¢ÉúÏà¹Ø²¢¿ÉÄܳÉΪÆäDZÔÚÖÎÁưе㡣YanµÈ[22]·¢ÏÖCTRP3ˮƽµÄ½µµÍÓëÌÇÄò²¡ÊÓÍøĤ²¡(DR)µÄ·¢Éú·¢Õ¹¼°ÆäÑÏÖس̶ÈÏà¹Ø¡£CTRP3ÔÚÈËÊÓÍøĤ΢Ѫ¹ÜÄÚƤϸ°ûÖÐͨ¹ýAMPKÒÀÀµÐÔ;¾¶¼õÇáÁ˸ßÌǸßÖ¬ÓÕµ¼µÄѪ¹Üϸ°ûÕ³¸½·Ö×Ó-1(VCAM-1)ÔöÖ³£¬ÌáʾCTRP3¿ÉÄܲÎÓëDRµÄÑ×Ö¢¹ý³Ì¡£ÇÒROCºÍAUC·ÖÎö±íÃ÷CTRP3ÊÇÔöÉúÐÍÌÇÄò²¡ÊÓÍøĤ²¡±äµÄ¶ÀÁ¢Ô¤²âÒò×Ó¡£ÐèÒª¸ü´óµÄÑù±¾Ñо¿À´Ö¤ÊµCTRP3¶ÔÌÇÄò²¡ÊÓÍøĤ¼²²¡ÑÏÖس̶ȵÄÔ¤²â¼ÛÖµ¼°ÆäDZÔÚµÄÖÎÁÆ×÷Óá£Óë¶ÔÕÕ×éÏà±È£¬ÑªÇåCTRP3ˮƽÔÚÌÇÄò²¡Éö²¡×éϽµ£¬²¢ÇÒÓë¹À¼ÆÉöСÇòÂ˹ýÂÊ£¬HO-MA-IR¶ÀÁ¢Ïà¹Ø[24]¡£HuµÈ[25]·¢ÏÖ¸ßÌǴ̼¤¿ÉÏÔ׎µµÍÉöϵĤϸ°ûÖÐCTRP3µÄ±í´ï¡£CTRP3ͨ¹ýʧ»îJAK 2/STAT 3ÐźÅͨ·À´ÒÖÖƸßÌÇÓÕµ¼µÄÉöСÇòϵĤϸ°ûÔöÖ³ºÍϸ°ûÍâ»ùÖʵIJúÉú¡£±íÃ÷ÁËCTRP3ÔÚÌÇÄò²¡Éö²¡ÖпÉÄܵı£»¤×÷Ó㬵«ÊÇÆä¾ßÌå»úÖÆÐèÒª¼ÌÐøÉîÈëÑо¿¡£

¡¡¡¡FlehmigµÈ(2014)¶Ô141¸öÁÙ´²Ñù±¾µÄ20¸öÖ¬·¾Òò×Ó(°üÀ¨CTRP3)ѪÇå±í´ïˮƽ½øÐÐÁ˼ì²â£¬²¢ÓëHbA1c¡¢HOMA-IRºÍ¿Õ¸¹ÑªÌÇÏà±È½Ï£¬·¢ÏÖËüÃÇÔ¤²âT2DMµÄÃô¸ÐÐÔ(78%¶Ô91%)¼°ÌØÒìÐÔ(76%¶Ô94%)¾ù½ÏµÍ¡£AhmedµÈ[7]ÔÚ¾ø¾­ºóÅ®ÐÔÖз¢ÏÖÓëT2DM×éÏà±È£¬T2DM²¢·¢CAD(¹ÚÐIJ¡)×éѪÇåCTRP3ˮƽ½µµÍ£¬¶øCAD×éѪÇåCTRP3ˮƽ×îµÍ¡£Òò´Ë£¬CTRP3¿ÉÓÃÓÚÕï¶Ï¡¢Ô¤ºóºÍ¸ú×ÙÓйÚÐIJ¡·çÏյľø¾­ºóÅ®ÐÔÌÇÄò²¡»¼Õß¡£Óë´úлÕý³£µÄ·ÊÅÖÕßÏà±È£¬6¸öÔµÄÒȵºËØ»ìºÏÎïÖÎÁƺó·ÊÅÖµÄ2ÐÍÌÇÄò²¡»¼ÕßѪÇåCTRP3ˮƽϽµ£¬¶øÖÐÐÔÁ£Ï¸°ûÃ÷½ºÃ¸Ïà¹ØÖ¬¸Æµ°°×(NGAL)¡¢ÍøĤËØ-1(omentin-1)ÉÏÉý[26]¡£±íÃ÷CTRP3ÔÚ¼à²â2ÐÍÌÇÄò²¡»¼ÕßÒȵºËØÖÎÁÆÏà¹ØµÄ´úл±ä»¯·½Ãæ¾ßÓÐDZÔÚµÄÕï¶Ï¼ÛÖµ¡£CTRP3¿ÉÄÜÉв»ÄÜÓÃÓÚÕï¶ÏT2DM£¬µ«ÔÚÆäËûÁÙ´²´úлÐÔ¼²²¡µÄÕï¶Ï¼°¸ÉÔ¤Ö®ºó½á¹ûµÄÔ¤²âÆÀ¹ÀÖÐÈÔÓÐÓ¦ÓõÄDZÁ¦¡£

¡¡¡¡(Èý)CTRP3ÓëÖ¬·¾¸Î

¡¡¡¡PetersonµÈ(2013)±íÃ÷ÁËCTRP3¶ÔÖ¬·¾¸Î¿ÉÄܾßÓб£»¤×÷Óã¬Ïà½ÏÓÚÒ°ÉúÐÍСÊó£¬CTRP3ת»ùÒòСÊó¶ÔÒûʳÓÕµ¼µÄ·ÊÅÖ(DIO)ËùÖµĸÎÔàÖ¬·¾±äÐԵķ¢Õ¹¾ßÓÐÃ÷ÏԵĵֿ¹Á¦£¬ÆäѪÇåTNF-αˮƽ½µµÍ£¬ÒȵºËØÃô¸ÐÐÔÒ²ÂÔÓиÄÉÆ¡£¶øÇÒÔÚÊóH4IIE¸Îϸ°ûÖУ¬ÖØ×éCTRP3¼õÉÙÁËÖ¬·¾ËáºÍÖÐÐÔÖ¬·¾µÄÀÛ»ý¡£

¡¡¡¡ZhouµÈ(2018)ÔÚ¶Ô313Ãû²ÎÓëÕß½øÐÐÈýÄêËæ·Ãºó·¢ÏÖѪÇåCTRP3ˮƽÓë·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÄ·¢Õ¹³Ê¸ºÏà¹Ø¡£ZhangµÈ[8]µÄÑо¿ÏÔʾÔÚ2ÐÍÌÇÄò²¡»¼ÕßÖл¼ÓзǾƾ«ÐÔÖ¬·¾¸ÎÕßµÄѪÇåCTRP3ˮƽµÍÓÚÎ޷Ǿƾ«ÐÔÖ¬·¾¸ÎÕߣ¬²¢ÇÒ±íÃ÷µÍѪÇåCTRP3ÊÇÖйú³õÕï2ÐÍÌÇÄò²¡»¼Õß»¼·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÄÖØÒªÔ¤²âÒòËØ¡£Õâ¸ö½á¹û½øÒ»²½Ö¤Ã÷ÁËѪÇåCTRP3ˮƽÓëÌÇ´úлºÍÖ¬´úл֮¼äDZÔÚµÄÁªÏµ£¬CTRP3¿ÉÄÜÊÇÌÇ¡¢Ö¬´úл֮¼äÁªÏµµÄÊàŦ£¬ÓÐÍû³ÉΪ´úлÐÔ¼²²¡ÖÎÁƵİе㡣DeGroatµÈ(2018)µÈ·¢ÏÖÔÚÒÒ´¼Î¹ÑøÄ£ÐÍÖдÆÐÔÊóµÄѪÇåCTRP3ˮƽϽµ£¬¶øÐÛÐÔÊóÖÐûÓб仯¡£TrogenµÈ[27]ÔÚ¶¯ÎïÄ£ÐÍÖз¢ÏÖCTRP3ÔÚ³¤ÆÚÂýÐÔ¶ø·Ç¶ÌÆÚÒû¾ÆµÄ×÷ÓÃÏ£¬¿É¼õÉÙ¸ÎÔà¸ÊÓÍÈýõ¥µÄ»ýÀÛ¡£±íÃ÷CTRP3¿ÉÄÜÓë¾Æ¾«ÐÔÖ¬·¾¸ÎµÄ²¡Àí·¢Õ¹Ïà¹Ø£¬ÇÒÔÚ²»Í¬ÐÔ±ðÖÐ×÷ÓÿÉÄÜ´æÔÚ²îÒì¡£

¡¡¡¡(ËÄ)CTRP3Óë¹Ç´úл

¡¡¡¡¹Ç¹Ø½ÚÑ׺͹ÇÖÊÊèËÉÖ¢Êdz£¼ûµÄÀÏÄêÍËÐÐÐÔ¼²²¡£¬²¢ÇÒ³£³£°éËæ·¢Éú¡£ÔÚ¾ø¾­ºó¸¾Å®ÖйÇÖÊÊèËÉ»¼ÕßѪÇåCTRP3ˮƽµÍÓÚ¶ÔÕÕ×飬ѪÇåCTRP3ˮƽÓë¹ÇÖÊÊèËɵͷçÏÕÏà¹Ø(µ÷ÕûÓÅÊƱÈ=0.973,95%¿ÉÐÅÇø¼ä)£¬Óë¹É¹Ç¹ÇÃܶȡ¢Ñü×µ¹ÇÃܶȳÊÕýÏà¹Ø[28]¡£»¼ÓÐÏ¥¸Ç¹Ç¹Ø½ÚÑ׵ľø¾­Å®ÐÔѪÇåCTRP3ˮƽµÍÓÚ¶ÔÕÕ×é[29]¡£ÐèÒª½øÐиü´óÑù±¾¼°¶ÔÐÔ±ð·Ö±ð½øÐÐÑо¿À´Ö¤ÊµCTRP3ˮƽµÄϽµÊÇÓÉÓÚ¹ÇÖÊÊèËɺ͹ǹؽÚÑ×¼²²¡»¹ÊÇÊÜÊÔÕß¾ø¾­ºó¼¤ËØˮƽµÄ±ä»¯¡£Ô­·¢ÐÔ¼××´ÅÔÏÙ¹¦ÄÜ¿º½øÖ¢»¼ÕßCTRP3ˮƽÃ÷ÏÔ½µµÍ£¬²¢Óë¹ÇÖÊÊèËÉÓйء£ÔÚLogistic»Ø¹é·ÖÎöÖУ¬Ö»ÓÐCTRP3ˮƽ¶ÀÁ¢¾ö¶¨¹ÇÖÊÊèËÉ£¬½µµÍCTRP3(ÿ1 ng/ml)ˮƽ¿Éʹ»¼Õß»¼¹ÇÖÊÊèËɵķçÏÕÔö¼Ó6.9%[30]¡£

¡¡¡¡Îå¡¢½áÓï

¡¡¡¡¹ØÓÚÖ¬·¾Òò×ÓCTRP3µÄÑо¿Ò²Ô½À´Ô½¹ã·ººÍÉîÈ룬Ðí¶àÑо¿±íÃ÷CTRP3ÔÚÐÄѪ¹Ü¡¢ÌÇÖ¬´úл¡¢¹Ç´úлµÈ·½Ãæ·¢»Ó×ÅÖØÒªµÄ±£»¤×÷Óã¬ÏÔʾÁËÆäÔÚÁÙ´²Ó¦ÓÃÖеľ޴óµÄDZÁ¦¡£¹ØÓÚCTRP3µÄÑо¿ÒÔÏ·½ÃæÐèÒªÒýÆð¹Ø×¢:(1)Ä¿Ç°Ñо¿±íÃ÷CTRP3Ôںܶ༲²¡ÖгÊϽµÇ÷ÊÆ£¬²¢ÓëÆäËüÖ¸±êÓÐÃ÷ÏÔÏà¹Ø¹Øϵ£¬µ«ÊÇÆäÄÜ·ñ×÷ΪÏà¹Ø¼²²¡µÄÁÙ´²Ô¤²â»òÕï¶ÏÖ¸±êÉÐÐè½øÒ»²½Ñо¿;(2)CTRP3ÊÜÌåµÄÃ÷È·¶ÔÑо¿Æä×÷Óü°ÁÙ´²µÄÓ¦ÓÃÓкܴóµÄ´Ù½ø×÷Ó㬵«ÊÇÄ¿Ç°ÈÔȱ·¦LAMP¢ñ¼°LIMP¢òÔڸΰ©Ï¸°ûϵµÄ¹¦ÄÜÑéÖ¤¼°ÔÚÆäËûϸ°ûÀàÐ͵ÄÑéÖ¤£¬²¢ÇÒÉÐÎÞÆäÔÚÔ­´úϸ°ûÖнøÐÐÑéÖ¤µÄÑо¿±¨µÀ;(3)²»Í¬À´Ô´µÄCTRP3¿ÉÄÜÔÚÏà¹Ø¼²²¡Öз¢»Ó²»Í¬µÄ×÷Ó㬱ÈÈçÖ¬·¾×éÖ¯ºÍÐļ¡Ï¸°ûÀ´Ô´µÄCTRP3¶ÔÐÄѪ¹Ü¼²²¡µÄ×÷ÓÃ;(4)³ÉÈËCTRP3ѪÇåˮƽÔÚ²»Í¬µÄ¼²²¡ÖдæÔÚÐÔ±ð²îÒ죬ÔÚ½øÐÐÑо¿Ê±Ó¦¿¼ÂÇÕâ¸öÒòËØ¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1] World Health Organization,2014.Global status report on noncommunicable diseases£®
¡¡¡¡[2] Li Y,Wright GL,Peterson M.C1q/TNF-related protein 3(CTRP3)function and regulation.Compr Physiol,2017,7¤X863~878£®
¡¡¡¡[3] Wolf RM,Lei X,Yang ZC,et al.CTRP3 deficiency reduces liver size and alters IL-6 and TGFbeta levels in obese mice.Am J Physiol Endocrinol Metab,2016,310¤XE332~E345£®
¡¡¡¡[4] Kwon MR,Cress E,Clark WA,et al.The adipokine C1q TNF related protein 3(CTRP3)is elevated in the breast milk of obese mothers.Peer J,2018,6¤Xe4472£®
¡¡¡¡[5] Chen NN,He JR,Li WD,et al.C1q and tumor necrosis factor-related protein 3 is present in human cord blood and is associated with fetal growth.Clin Chim Acta,2016,453¤X67~70£®
¡¡¡¡[6] Wagner RM,Sivagnanam K,Clark WA,et al.Divergent relationship of circulating CTRP3 levels between obesity and gender:a cross-sectional study.PEERJ,2016,4¤Xe2573£®
¡¡¡¡[7] Ahmed SF,Shabayek MI,Abdel Ghany ME,et al.Role of CTRP3,CTRP9 and MCP-1 for the evaluation of T2DM associated coronary artery disease in Egyptian postmenopausal females.PLo S ONE,2018,13¤Xe0208038£®
¡¡¡¡[8] Zhang J,Zhang B,Cheng Y,et al.Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.Cytokine,2018,106¤X131~135
¡¡¡¡[9] Gao C,Zhao S,Lian K,et al.C1q/TNF-related protein 3(CTRP3)and 9(CTRP9)concentrations are decreased in patients with heart failure and are associated with increased morbidity and mortality.BMC Cardiovasc Disor,2019,19¤X139£®
¡¡¡¡[10] Yi W,Sun Y,Yuan Y,et al.C1q/tumor necrosis factor-related protein-3,a newly identified adipokine,is a novel antiapoptotic,proangiogenic,and cardioprotective molecule in the ischemic mouse heart.Circulation,2012,125¤X3159~3169£®
¡¡¡¡[11] Zhang Z,Zhu L,Feng P,et al.C1q/tumor necrosis factorrelated protein-3-engineered mesenchymal stromal cells attenuate cardiac impairment in mice with myocardial infarction.Cell Death Dis,2019,10¤X530£®
¡¡¡¡[12] Zhang Z,Zhu L,Feng P,et al.C1q-TNF-related protein-3attenuates pressure overload-induced cardiac hypertrophy by suppressing the p38/CREB pathway and p38-induced ERstress.Cell Death Dis,2019,10¤X520
¡¡¡¡[13] Ma ZG,Yuan YP,Zhang X,et al.C1q-tumor necrosis factor-related protein-3 exacerbates cardiac hypertrophy in mice.Cardiovasc Res,2019,115¤X1067~1077£®
¡¡¡¡[14] Ma ZG,Yuan YP,Xu SC,et al.CTRP3 attenuates cardiac dysfunction,inflammation,oxidative stress and cell death in diabetic cardiomyopathy in rats.Diabetologia,2017,60¤X1126~1137£®
¡¡¡¡[15] Wei WY,Ma ZG,Zhang N,et al.Overexpression of CTRP3 protects against sepsis-induced myocardial dysfunction in mice.Mol Cell Endocrinol,2018,476¤X27~36£®
¡¡¡¡[16] Yuan YP,Ma ZG,Zhang X,et al.CTRP3 protected against doxorubicin-induced cardiac dysfunction,inflammation and cell death via activation of Sirt1.J Mol Cell Cardiol,2018,114¤X38~47£®
¡¡¡¡[17] Lin J,Liu Q,Zhang H,et al.C1q/Tumor necrosis factorrelated protein-3 protects macrophages against LPS-induced lipid accumulation,inflammation and phenotype transition via PPARγand TLR4-mediated pathways.Oncotarget,2017,8¤X82541~82557£®
¡¡¡¡[18] Chen L,Qin L,Liu X,et al.CTRP3 alleviates Ox-LDL-induced inflammatory response and endothelial dysfunction in mouse aortic endothelial cells by activating the PI3K/Akt/e NOS pathway.Inflammation,2019,42¤X1350~1359£®
¡¡¡¡[19] Liu Y,Li LN,Guo S,et al.Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction.Redox Biol,2018,18¤X211~221£®
¡¡¡¡[20] Jiang H,Wang M,Ye J,et al.Serum levels of complementC1q/tumor necrosis factor-related protein-3 decreased in patients with acute aortic dissection.Am J Cardiol,2018,122¤X1244~1248£®
¡¡¡¡[21] Nishimoto H,Yamamoto A,Furukawa S,et al.C1q/TNF-related protein 3 expression and effects on adipocyte differentiation of 3T3-L1 cells.Cell Biol Int,2017 Feb;41¤X197~203£®
¡¡¡¡[22] Yan Z,Zhao J,Gan L,et al.CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner.Plo S One,2017,12¤Xe0178253£®
¡¡¡¡[23] Li X,Jiang L,Yang M,et al.Impact of weight cycling on CTRP3 expression,adipose tissue inflammation and insulin sensitivity in C57BL/6J mice.Exp Ther Med,2018,16¤X2052~2059£®
¡¡¡¡[24] Moradi N,Fadaei R,Khamseh ME,et al.Serum levels of CTRP3 in diabetic nephropathy and its relationship with insulin resistance and kidney function.PLo S ONE,2019,14¤Xe0215617£®
¡¡¡¡[25] Hu TY,Li LM,Pan YZ.CTRP3 inhibits high glucose-induced human glomerular mesangial cell dysfunction.J Cell Biochem,2019,120¤X5729~5736£®
¡¡¡¡[26] Komosinska-Vassev K,Olczyk P,Kuznik-Trocha K,et al.Circulating C1q/TNF-related protein omentin-1 and NGALin obese patients with type 2 diabetes during insulin therapy.J Clin Med,2019,8¤X805£®
¡¡¡¡[27] Trogen G,Bacon J,Li Y,et al.Transgenic overexpression of CTRP3 prevents alcohol-induced hepatic triglyceride accumulation.Am J Physiol Endocrinol Metab,2018,315¤XE949~E960£®
¡¡¡¡[28] Xu ZH,Zhang X,Xie H,et al.Serum CTRP3 level is associated with osteoporosis in postmenopausal women.Exp Clin Endocrinol Diabetes,2018,126¤X559~563£®
¡¡¡¡[29] Maghbooli Z,Hossein-Nezhad A,Khoshechin G,et al.Possible association between circulating CTRP3 and knee osteoarthritis in postmenopausal women.Aging Clin Exp Res,2019,31¤X927~934£®
¡¡¡¡[30] Demirtas D,Aclbucu F,Baylan FA,et al.CTRP3 is significantly decreased in patients with primary hyperparathyroidism and closely related with osteoporosis.Exp Clin Endocrinol Diabetes,2019,PMID¤X31117148.

×÷Õßµ¥Î»£ºÑÓ°²´óѧÑо¿ÉúÔº ÑÓ°²´óѧ¸½ÊôÒ½ÔºÐÄѪ¹ÜÄÚ¿Æ
Ô­Îijö´¦£ººúÏþ,³£Ð¡Ù»,ËÎÑÓ±ò.CTRP3Ñо¿Ð½øÕ¹[J].ÉúÀí¿Æѧ½øÕ¹,2020,51(04):299-304.
Ïà¹ØÄÚÈÝÍƼö
Ïà¹Ø±êÇ©£º
·µ»Ø£º²¡ÀíѧÂÛÎÄ